VBI Vaccines Inc. (NASDAQ:VBIV – Get Free Report) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 302,500 shares, a drop of 18.9% from the April 30th total of 372,800 shares. Currently, 1.2% of the shares of the company are short sold. Based […]
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response and two stable disease observations have occurred as of May 15,.
StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a research note released on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. VBI Vaccines Stock Down 1.4 % Shares of VBIV stock opened at $0.64 on Monday. The business has a 50-day moving average price of […]
VBI Vaccines Inc. , a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the.
VBI Vaccines Inc. announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company s cancer vaccine immunotherapeutic candidate in.